Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of anamorelin in non-small cell lung cancer cachexia
jRCT2080221376Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) and non-small cell lung cancer (NSCLC) comparing Anamorelin 100 mg with Placebo (2 arms). Started Feb 2011; status: completed.
02
Drugs
anamorelin
03
Conditions
cancer anorexia-cachexia syndrome (CACS)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221376.